醫藥品產業的授權契約 (2020-2025年)

本報告提供了2020年至2025年製藥業授權協議的詳細資訊。它提供了各方宣布的許可協議的付款條款，並提供了有關付款條款和其他交易條款的寶貴見解。

主要優勢

本報告提供讀者以下主要優勢：

• 了解2020年及以後的合約趨勢
• 瀏覽許可協議
• 基準分析：了解交易的市場價值
• 財務條款：有關預付款、里程碑付款和特許權使用費的信息
• 合約目錄：依公司（A-Z）、治療領域、技術類型分類
• 按價值劃分的主要合約
• 識別最活躍的承包商
• 識別每筆交易的資產和條款
• 存取合約文件：深入了解合約結構
• 盡職調查：評估您的合約條款與合作夥伴的一致性
• 節省數百小時的研究時間

調查範圍

• 生物製藥產業的授權協議趨勢
• 許可協議結構概述
• 製藥和生物技術領域許可協議記錄目錄
• 按價值劃分的主要授權協議
• 最活躍的許可公司
• 主要的許可合作夥伴資源

可利用契約的清單:

• 企業 (A～Z)
• 契約總額
• 治療領域
• 技術類型

目錄

摘要整理

第1章 簡介

第2章 授權交易趨勢

• 授權契約定義
• 2020年以後的授權契約趨勢
  • 2020～2025年的授權契約:各年度
  • 2020～2025年的授權契約:各開發階段
  • 2020～2025年的授權契約:各業界
  • 2020～2025年的授權契約:各治療領域
  • 2020～2025年的授權契約:各技術類型
  • 2020～2025年的授權契約:最活躍的各企業
• 原因建立許可合作關係
• 許可協議的未來

第3章 授權契約結構:概要

• 授權契約結構

第4章 主要授權契約

• 首位授權契約:各金額

第5章 最活躍的授權契約企業:前25家

• 最活躍的授權契約企業:前25家

第6章 含契約名錄的授權契約

• 包含從2020年到2025年契約的授權契約
• 契約名錄
• 契約名錄- 各企業授權契約 (A-Z)
• 契約名錄- 各治療領域的授權契約
• 契約名錄- 各技術類型的授權契約
• 關於Biopharma Research
• 目前聯盟
• 目前契約
• Current Partnering的最近報告標題

Licensing Deals in Pharmaceuticals provides a detailed understanding and analysis of how and why companies enter licensing deals.

Fully revised and updated, the report provides details of licensing deals from 2020 to 2025.

The report provides access to licensing deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of licensing deals announced since 2020 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of licensing dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in licensing as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of licensing deals.

Chapter 4 provides a review of the leading licensing deals since 2020. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active licensing dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of licensing deals organized by company A-Z, therapy, technology and industry type signed and announced since 2020 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the licensing deal.

The deal directory includes a comprehensive listing of all licensing deals announced since 2020. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in licensing dealmaking since 2020.

In conclusion, this report provides everything a prospective dealmaker needs to know about licensing alliances.

Key benefits

Licensing Deals in Pharmaceuticals provides the reader with the following key benefits:

• Understand deal trends since 2020
• Browse licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Licensing Deals in Pharmaceuticals is intended to provide the reader with an in-depth understanding of the licensing trends and structure of deals entered into by leading biopharma companies worldwide.

Licensing Deals in Pharmaceuticals includes:

• Trends in licensing dealmaking in the biopharma industry
• Overview of licensing deal structure
• Directory of licensing deal records covering pharmaceutical and biotechnology
• The leading licensing deals by value
• Most active licensing dealmakers
• The leading licensing partnering resources

In Licensing Deals in Pharmaceuticals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Licensing Deals in Pharmaceuticals provides comprehensive access to available records for licensing deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in licensing dealmaking

• 2.1. Introduction
• 2.2. Definition of licensing deal
• 2.3. Trends in licensing deals since 2020
  • 2.3.1. Licensing dealmaking by year, 2020-2025
  • 2.3.2. Licensing dealmaking by phase of development, 2020-2025
  • 2.3.3. Licensing dealmaking by industry sector, 2020-2025
  • 2.3.4. Licensing dealmaking by therapy area, 2020-2025
  • 2.3.5. Licensing dealmaking by technology type, 2020-2025
  • 2.3.6. Licensing dealmaking by most active company, 2020-2025
• 2.4. Reasons for entering into licensing partnering deals
• 2.5. The future of licensing deals

Chapter 3 - Overview of licensing deal structure

• 3.1. Introduction
• 3.2. Licensing agreement structure

Chapter 4 - Leading licensing deals

• 4.1. Introduction
• 4.2. Top licensing deals by value

Chapter 5 - Top 25 most active licensing dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active licensing dealmakers

Chapter 6 - Licensing deals including contracts directory

• 6.1. Introduction
• 6.2. Licensing deals with contracts 2020-2025
• Deal directory
• Deal directory - licensing dealmaking by companies A-Z
• Deal directory - licensing dealmaking by therapy area
• Deal directory - licensing dealmaking by technology type
• About Biopharma Research
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of licensing
• Figure 2: Trends in licensing deal announcements, 2020-2025
• Figure 3: Licensing deals signed at each phase of development, 2020-2025
• Figure 4: Licensing deals by industry sector, 2020-2025
• Figure 5: Licensing deals by therapy area, 2020-2025
• Figure 6: Licensing deals by technology type, 2020-2025
• Figure 7: Top 25 most active licensing dealmakers, 2020-2025
• Figure 8: Top licensing deals by value, 2020-2025
• Figure 9: Most active licensing dealmakers, 2020-2025